<DOC>
	<DOCNO>NCT03062540</DOCNO>
	<brief_summary>This 12-week , multicenter , randomize , double-blind , placebo-controlled , fixed-dose study investigate efficacy safety 5.6 mg TNX-102 SL ( 2 x 2.8 mg tablet ) —a sublingual formulation cyclobenzaprine . Following successful screen randomization , eligible patient telephonic visit week 2 return regularly study clinic monthly visit assessment efficacy safety .</brief_summary>
	<brief_title>Safety Efficacy Study TNX-102 SL Patients With Military-related PTSD</brief_title>
	<detailed_description />
	<mesh_term>Cyclobenzaprine</mesh_term>
	<criteria>Male female 18 75 year age , serve branch military . Diagnosed current PTSD determine ClinicianAdministered PTSD Scale ( CAPS5 ) DSM5 . Index trauma ( ) result PTSD must meet DSM5 criterion A PTSD describe CAPS5 , occur 2001 later , military service relate . Willing refrain use formulation cyclobenzaprine . Willing able refrain antidepressant exclude medication . Capable read understand English able provide write informed consent . If female , either childbearing potential practicing medically acceptable method birth control throughout study . Willing able comply protocolspecified requirement . Increased risk suicide , base investigator 's judgment severity appropriate outpatient management , warrant additional therapy exclude protocol . Significant ( e.g. , moderate severe ) comorbid traumatic brain injury ( TBI ) history . Severe depressive symptom screen baseline base score ≥29 BDIII Visits 1 2 . Clinically significant laboratory abnormality base screen laboratory test and/or medical history investigator 's opinion . Use antidepressant medication within 2 month baseline . Female patient pregnant lactate . History serotonin syndrome , severe allergic reaction bronchospasm know hypersensitivity cyclobenzaprine excipients . Seizure disorder . Patients body mass index ( BMI ) &gt; 45 . Has receive investigational drug within 30 day Screening . Previous participation study TNX102 SL . Family member investigative staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>PTSD</keyword>
	<keyword>Military-related PTSD</keyword>
</DOC>